AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8970892
Drug: Three consecutive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive oral phosphate doses (3 x 500 mg in water)
Trial: 1728934
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg gemfibrozil (two 300 mg capsules twice daily)
Trial: 1728934
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg gemfibrozil (one 600 mg tablet twice daily)
Trial: 1728934
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg gemfibrozil (two 450 mg tablets in the evening)
Trial: 1728934
Drug: gemfibrozil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil (all formulations)
Trial: 1728934
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg gemfibrozil
Trial: 6365235
Drug: Oral amoxycillin
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral amoxycillin (3 g) and clavulanate (250 mg)
Trial: 6365235
Drug: Intramuscular procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular procaine penicillin (2.4 MU)
Trial: 26717223
Drug: 60-mg prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg prasugrel loading dose
Trial: 26717223
Drug: Clopidogrel standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel standard dose
Trial: 21800004
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day n3‐PUFA
Trial: 19501883
Drug: Doxazosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin plus tenoxicam 20 mg
Trial: 12401122
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg
Trial: 10681323
Drug: Lamivudine 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 0.35 mg/kg twice daily
Trial: 10681323
Drug: Lamivudine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 1.5 mg/kg twice daily
Trial: 10681323
Drug: Lamivudine 4
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine 4 mg/kg twice daily
Trial: 10681323
Drug: Lamivudine 3
RxNorm normalized name: lamivudine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 3 mg/kg once daily
Trial: 10681323
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg (tablets) for adolescents
Trial: 9322520
Drug: Lamivudine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (all doses)
Trial: 10681323
Drug: Lamivudine 3
RxNorm normalized name: lamivudine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 3 mg/kg/day
Trial: 15078377
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (1 mg/kg)
Trial: 9316958
Drug: Caudal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal analgesia (1 ml/kg 0.20% bupivacaine with 1/200,000 epinephrine)
Trial: 25815324
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein daily
Trial: 25815324
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lutein daily
Trial: 25815324
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 10 mg lutein and 10 mg zeaxanthin daily
Trial: 21925062
Drug: MLC601 (NeuroAiD™),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLC601 (NeuroAiD™), 4 capsules, 3 times a day for 3 months
Trial: 21925062
Drug: Placebo, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 4 capsules, 3 times a day for 3 months
Trial: 18283598
Drug: Levonorgestrel administered
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel administered alone
Trial: 18283598
Drug: Mifepristone (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (selective progesterone receptor modulator)
Trial: 8794800
Drug: Dipyrone, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone, 2.5 g
Trial: 8794800
Drug: Nitroglycerin, 1
RxNorm normalized name: Nitroglycerin, 100 mcg/mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin, 1 mg
Trial: 8794800
Drug: N‐butylscopolamine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐butylscopolamine, 20 mg
Trial: 8794800
Drug: Tramadol, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol, 50 mg
Trial: 8794800
Drug: Indomethacin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 75 mg
Trial: 1616158
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg rocuronium (n = 20)
Trial: 1616158
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg succinylcholine (n = 10)
Trial: 778987
Drug: Sulindac (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (400 mg/day)
Trial: 1092727
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg/day)
Trial: 26120052
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (intramuscular testosterone undecanoate for 40 weeks)
Trial: 25070809
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX) 100 mg/d
Trial: 25070809
Drug: Modified Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Behavioral Self-Control Therapy (MBSCT)
Trial: 25070809
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Compliance Enhancement Treatment (BBCET)
Trial: 22585094
Drug: 20-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-week group treatment in addition to treatment as usual
Trial: 9462588
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents (APAs)
Trial: 12836712
Drug: Enalapril therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril therapy
Trial: 8046423
Drug: Quadrivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent vaccine (1 x 10(4) PFU each of D x RRV and RRV, followed 4 weeks later by 1 x 10(4) PFU each of DS1 x RRV and ST3 x RRV)
Trial: 8046423
Drug: Quadrivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent vaccine (10(4) PFU of each component)
Trial: 8046423
Drug: M37 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M37 vaccine (10(4) PFU)
Trial: 8046423
Drug: Higher-titered quadrivalent
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-titered quadrivalent vaccine (10(5) PFU of each component)
Trial: 8046423
Drug: Higher-titered M37
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-titered M37 vaccine (10(5) PFU)
Trial: 2902873
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg acebutolol
Trial: 31868889
Drug: Therapy A
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy A - Bolus water drinking + physical counter‐manoeuvres (PCM)
Trial: 31868889
Drug: Therapy B
RxNorm normalized name: Therapy Bayer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy B - Bolus water drinking + PCM + abdominal compression
Trial: 31868889
Drug: Single therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single therapy (bolus water drinking)
Trial: 16645968
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronic acid (5 mg)
Trial: 9684701
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) (6,160 IU +/- 1,350 IU)
Trial: 9684701
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) (15 anti-Xa U/kg + 5 anti-Xa U/kg/h)
Trial: 2904367
Drug: Vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg kg‐1 (divided dose)
Trial: 2904367
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg kg‐1 (divided dose)
Trial: 2904367
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg kg‐1 (single dose)
Trial: 2904367
Drug: Pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.1 mg kg‐1 (divided dose)
Trial: 21270326
Drug: iv recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv recombinant hCG (1, 10, 25, 100, and 250 μg)
Trial: 21270326
Drug: iv recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv recombinant hCG (25 μg)
Trial: 19481579
Drug: Deltoid injection
RxNorm normalized name: Ambrosia deltoidea pollen
DrugBank: Ambrosia deltoidea pollen (DB10765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltoid injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Trial: 19481579
Drug: Gluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluteal injection of paliperidone palmitate (50, 75, or 100 mg eq.)
Trial: 19481579
Drug: Deltoid and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltoid and gluteal injections of paliperidone palmitate
Trial: 16923411
Drug: High-dose folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose folic acid multivitamin (5 mg folic acid, 50 mg vitamin B6, 1000 microg vitamin B12)
Trial: 16923411
Drug: Low-dose folic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose folic acid multivitamin (0 mg folic acid, 1.4 mg vitamin B6, 2 microg vitamin B12)
Trial: 14970765
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment using pulsed electromagnetic fields
Trial: 14970765
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for patients with anterior disk displacement without reduction
Trial: 14970765
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for patients with osteoarthritis
Trial: 14970765
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for patients with anterior disk displacement with reduction
Trial: 2330731
Drug: 1-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day treatment with sulfamerazine/trimethoprim (Berlocombin)
Trial: 2330731
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment with regular sulfamerazine/trimethoprim (Berlocombin)
Trial: 2330731
Drug: 7-day treatment
RxNorm normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day treatment with reduced sulfamerazine/trimethoprim (Berlocombin)
Trial: 24585363
Drug: Arthroscopic capsular
RxNorm normalized name: Haemophilus capsular oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic capsular release including release of the rotator interval and anterior and inferior capsule (Group I, n = 37)
Trial: 24585363
Drug: Arthroscopic capsular
RxNorm normalized name: Haemophilus capsular oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic capsular release extended to the posterior capsule (Group II, n = 38)
Trial: 29653649
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg BID
Trial: 20141630
Drug: Cryotherapy using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy using liquid nitrogen for a maximum of 4 treatments (2-3 weeks apart)
Trial: 20141630
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid (50%) self-treatment for a maximum of 8 weeks
Trial: 18043528
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) for 12 weeks
Trial: 16086929
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment arms
Trial: 10354026
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further corticosteroid treatment (group C)
Trial: 1354687
Drug: Tocopherol (dl-alpha-tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocopherol (dl-alpha-tocopherol nicotinate, 200 mg, tid)
Trial: 1354687
Drug: Tocopherol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocopherol (200 mg, tid)
Trial: 6499511
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg meptazinol every 3 to 6 hours as required for 72 hours
Trial: 29042063
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (10 mL)
Trial: 29042063
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (5 mL)
Trial: 23050557
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum CJLP133 (0.5 × 10^10 CFU, twice a day for 12 weeks)
Trial: 27584578
Drug: Arginine deprivation
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine deprivation with ADI-PEG20 (36.8 mg/m2, weekly intramuscular) plus best supportive care (BSC)
Trial: 26625989
Drug: 1% subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% subcutaneous lidocaine
Trial: 26625989
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia regime comprising systemic anti‐inflammatory agents and opioids
Trial: 23263241
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg/day
Trial: 19134126
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5% SAP and 0.2% retinol
Trial: 16786230
Drug: Extended-duration thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-duration thromboprophylaxis with enoxaparin 40 mg subcutaneously once daily for an additional 28 +/- 4 days
Trial: 16786230
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of enoxaparin 40 mg subcutaneously once daily for 10 +/- 4 days
Trial: 11389491
Drug: Cefoperazone-sulbactam plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone-sulbactam plus cotrimoxazole (cefoperazone 25 mg/kg/day, TMP-SMZ at a ratio of 80:400, TMP 8 mg/kg/day)
Trial: 11389491
Drug: Ceftazidime plus
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime plus cotrimoxazole (ceftazidime 100 mg/kg/day, TMP-SMZ at a ratio of 80:400, TMP 8 mg/kg/day)
Trial: 8978577
Drug: UFT (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (350 mg/m2/day orally x 14 days)
Trial: 8978577
Drug: 5-FU (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (500 mg/m2 I.V. days 1 and 8)
Trial: 24519752
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab plus chemotherapy
Trial: 22360924
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone plus orally administered 17 Beta estradiol
Trial: 24215741
Drug: Sandwich bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich bone augmentation (SBA) technique
Trial: 24215741
Drug: Sandwich bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich bone augmentation (SBA) technique with critical crest angulation (CA) < 150°
Trial: 24215741
Drug: Sandwich bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandwich bone augmentation (SBA) technique with critical crest angulation (CA) > 150°
Trial: 23461841
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg glucophage po bid for 12 weeks
Trial: 23461841
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg magnesium oxide po bid for 12 weeks
Trial: 23461841
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg spironolactone po bid for 12 weeks
Trial: 15230484
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg AT-1015 BID
Trial: 15230484
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg AT-1015 BID
Trial: 15230484
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg AT-1015 BID
Trial: 9386849
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (n = 21)
Trial: 9386849
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) (n = 8)
Trial: 7970064
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (parnaparin)
Trial: 3299090
Drug: Oral azidothymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azidothymidine (AZT)
Trial: 29746726
Drug: Generic candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic candesartan 16 mg
Trial: 29746726
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation
Trial: 27585757
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive treatment strategy (aiming for revascularisation within 7 days)
Trial: 17604045
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive treatment strategy
Trial: 20802322
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (10% solution of pentastarch)
Trial: 18187744
Drug: Sildenafil (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20, 40, or 80 mg three times daily)
Trial: 8352673
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride (20 mg)
Trial: 8352673
Drug: Clonidine hydrochloride
RxNorm normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine hydrochloride (0.1 mg)
Trial: 8352673
Drug: Drug-treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-treated group (overall)
Trial: 3602599
Drug: Ambroxol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (30 mg tablet 3 times/day for adults; 9 mg syrup 4 times/day for children)
Trial: 31272404
Drug: Parent-led strategies
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-led strategies informed by behavioral economics implemented in 6 weekly cooking skills classes
Trial: 28836285
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instruction (OHI), scaling and root debridement (n = 11)
Trial: 21136011
Drug: edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edoxaban 30 mg qd
Trial: 21136011
Drug: edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edoxaban 60 mg qd
Trial: 21136011
Drug: warfarin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin (dose adjusted to INR of 2-3)